NYSE · PBHHealthcarePharmaceuticals

Prestige Consumer Healthcare financials

$46.74−0.40%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ1 '27
Jun 30
Q4 '26
Mar 31
Q3 '26
Dec 31
Q2 '26
Sep 30
Q1 '26
Jun 30
Q4 '25
Mar 31
Q3 '25
Dec 31
Q2 '25
Sep 30
Q1 '25
Jun 30
Q4 '24
Mar 31
Q3 '24
Dec 31
Q2 '24
Sep 30
Revenue$265.7M$281.6M$283.4M$274.1M$249.5M$296.5M$290.3M$283.8M$267.1M$277.0M$282.7M$286.3M
Gross profit$136.2M$146.3M$157.4M$151.6M$140.3M$170.0M$161.0M$157.4M$146.0M$151.8M$157.9M$160.0M
Gross margin51.3%51.9%55.5%55.3%56.2%57.3%55.5%55.5%54.7%54.8%55.9%55.9%
Operating income$52.5M$75.5M$82.5M$79.7M$71.8M$88.4M$92.0M$84.3M$72.0M$82.2M$86.8M$88.3M
Net income$29.2M$53.9M$46.7M$42.2M$47.5M$50.1M$61.0M$54.4M$49.1M$49.5M$53.0M$53.6M
Net margin11.0%19.1%16.5%15.4%19.0%16.9%21.0%19.2%18.4%17.9%18.8%18.7%
Diluted EPS$0.61$1.13$0.97$0.86$0.95$1.00$1.22$1.09$0.98$0.98$1.06$1.07
EBITDA$61.3M$83.8M$90.1M$87.3M$79.4M$108.1M$98.8M$92.3M$80.2M$82.2M$94.5M$95.9M
Operating cash flow$70.8M$42.8M$78.3M$57.5M$79.0M$61.8M$65.1M$69.8M$54.8M$66.9M$71.5M$62.5M
Free cash flow$67.1M$37.6M$75.3M$55.4M$78.2M$58.4M$63.5M$67.8M$53.6M$63.8M$69.5M$59.5M
Diluted shares47.6M47.7M48.1M49.3M49.8M50.1M50.0M50.0M50.3M50.3M50.1M50.1M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$89.1M$63.9M$62.4M$119.1M$139.5M$97.9M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$2.04B$1.01B$1.05B$1.02B$1.02B$1.02B
Total assets$4.57B$3.49B$3.49B$3.44B$3.43B$3.40B
Total liabilities$2.65B$1.61B$1.67B$1.62B$1.58B$1.57B
Shareholders' equity$1.92B$1.89B$1.83B$1.82B$1.86B$1.83B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology